FDA Approves Ultragenyx Gene Therapy

The FDA has approved a gene therapy from Ultragenyx, according to STAT News, which reported the decision on August 20, 2026, in its biotech roundup “The Readout.” The outlet did not detail the therapy’s mechanism, indication, or trial data in the material available here.

The same roundup noted that Regeneron secured approval for a drug treating an ultra-rare disease, a result STAT News characterized as a validating win for mRNA research. No further specifics on the Regeneron approval, including the disease it targets or the clinical evidence behind it, were provided in the cited summary.

Both items appeared together in STAT’s regular column tracking developments across the biotechnology industry, alongside unspecified additional news the outlet grouped under the same August 20 dispatch. The report is behind STAT’s subscription paywall (STAT+), and the source material reviewed here consists of the outlet’s own headline and summary language rather than the full text of the underlying article.

No independent confirmation, regulatory filing number, or FDA statement is included in the available reporting. Readers seeking the specific product name, approved indication, or supporting trial data for either the Ultragenyx or Regeneron decisions will need to consult STAT’s full article directly, as those details fall outside what the summary provided to this desk contains.